Advances in HLA Matching for Unrelated Donor Transplantation Dennis L. Confer, M.D. Chief Medical Officer National Marrow Donor Program Minneapolis, Minnesota.

Slides:



Advertisements
Similar presentations
Considerations for Analyzing Targeted NGS Data HLA
Advertisements

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
HLA: matching and donor selection
PRA = 36% (21/58) Anti-A11 and B44.
Acceptable mismatches based on structural epitopes on HLA molecules Toulouse, April 2, 2008.
HLA TYPING D Middleton MDSC175: Transplantation Science for Transplant Clinicians (Online) POSTGRADUATE SCHOOL OF MEDICINE A MEMBER OF THE RUSSELL GROUP.
High Resolution HLA Matching in Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,
Objectives Overview of HLA genes and their function
FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.
Medical Interventions
One Chance in a Million: An equilibrium Analysis of Bone Marrow Donation Ted Bergstrom, Rod Garratt Damien Sheehan-Connor.
Finding Stem Cell Donors For Mixed-Race Patients Ted Bergstrom, Rod Garratt, Damien Sheehan-Connor Univ of California Santa Barbara.
DNA-Based Tissue Typing
successful HSCT depends on many factors
The Major Histocompatibility Complex And Antigen Presentation
Pre-HSCT Donor & Patient Investigations: HLA Typing BBMT Society of Nigeria July 2013 Pre-HSCT Donor & Patient Investigation: HLA Typing Anthony.
Donor Selection for HSCT
SOLID PHASE IMMUNOASSAYS: INTERPRETING PATTERNS Julie Houp, CHS Johns Hopkins University School of Medicine Division of Immunogenetics and Transplantation.
New Approaches for Addressing Long Term Survivorship in Transplant Patients Dennis L. Confer, M.D. Chief Medical Officer National Marrow Donor Program.
Tissue Typing. E VERYONE HAS SEVERAL ANTIGENS LOCATED ON THE SURFACE OF HIS / HER LEUKOCYTES : One particular group of these antigens is called the HLA.
Dennis L. Confer, M.D. Chief Medical Officer, NMDP The National Marrow Donor Program Research Sample Repository: A Resource in Jeopardy.
The basics of Marrow Things to know.... Reasons to hold a marrow drive: ›Patient Focused ›Potential for large minority turnout ›Saturn National Donor.
Transplantation immunology Dr Adel Almogren.. Transfusion vs. Transplantation  Transfusion  transfer of blood  Ab-mediated reactions  Transplantation.
The genetic bases BY Casey Jaroche
11 22 33  m 11 22 33 11 22 11 22 Classical MHC I human MICA, B ULBP-human RAE-1- like human NKG2D-ligands mouse NKG2D-ligands RAE-1,
STATE HEALTH PLAN REQUEST FOR REVIEW OF DONOR COVERAGE BENEFITS Presented by: S. Elizabeth Sharf August 2015.
IMMUNOGENETIC TESTS.
Major Histocompatibility Complex and Transplantation Major histocompatibility complex (MHC) proteins were discovered for the first time with the advent.
1. HLA Typing 2 Introduction Each year many people worldwide are diagnosed with leukaemia or other fatal blood disorders. Bone marrow or stem cell transplantation.
Fe A. Bartolome, MD, FPASMAP Department of Microbiology Our Lady of Fatima University.
MAJOR HISTOCOMPATIBILITY COMPLEX. MAJOR HISTOCOMPATIBILITY COMPLEX (MHC): Is a segment of the short arm (p) of chromosome 6 containing several genes These.
In The Name of GOD Genetic Polymorphism M.Dianatpour MLD,PHD.
Transplantation Immunology Unit College of Medicine
Transplantation Prof. Zahid Shakoor College of Medicine King Saud University.
N ATIONAL M ARROW D ONOR P ROGRAM ® Entrusted to operate the C.W. Bill Young Cell Transplantation Program, including the Be The Match Registry SM Advances.
Creating Connections. Saving Lives. ™ NATIONAL MARROW DONOR PROGRAM ® Enhancing Donor Selection: Building Blocks of the New Search Algorithm NMDP Council.
Nancy Reau, MD University of Chicago Chicago, Illinois Mark S. Sulkowski, MD Johns Hopkins University School of Medicine Baltimore, Maryland Clinical Outcomes.
Major Histocompatibility Complex (MHC) Human Leukocyte Antigen (HLA)
HAPLOIDENTICAL STEM CELL TRANSPLANT
Christian Gabriel, Linz
New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.
ABILITY OF MINORITY PATIENTS TO FIND DONORS FROM AN ETHNICALLY DIVERSE CORD BLOOD BANK Lee Ann Baxter-Lowe, Ph.D., Young Kim, M.S., Shelly Carter, Sc.D.,
Matthew Raymond Smith, MD, PhD Professor of Medicine Harvard Medical School Program Director, Genitourinary Oncology Massachusetts General Hospital Cancer.
Anajane G. Smith1, 2 Shalini E. Pereira1, 2 Dan E. Geraghty1, 2
Plasma Droplet Digital PCR for Detection of EGFR and KRAS Mutations in Patients With Advanced Nonsquamous NSCLC Slideset on: Sacher AG, Paweletz C, Dahlberg.
Major Histocompatibility Complex
Transplantation Immunology Unit College of Medicine
Transplantation Immunology Unit College of Medicine
Transplantation Pathology
DNA Analysis of the HLA Gene Complex
Major Histocompatibility complex OR
Major Histocompatibility complex OR
Marcelo Pando UNOS Region 5 Collaborative March, 2017
EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants
Molecular Typing Shows a High Level of HLA Class I Incompatibility in Serologically Well Matched Donor/Patient Pairs: Implications for Unrelated Bone Marrow.
Major Histocompatibility Complex
Richard G. Phelps, Andrew J. Rees  Kidney International 
HLA-Class I: Typing Theory
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Figure 1 HLA-haploidentical donors
National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants  Robert A. Bray, Carolyn K. Hurley, Naynesh.
8/8 and 10/10 High-Resolution Match Rate for the Be The Match Unrelated Donor Registry  Jason Dehn, Kelly Buck, Martin Maiers, Dennis Confer, Robert Hartzman,
HLA DNA Typing and Transplantation
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Identification of DPB1 Permissive Unrelated Donors Is Highly Likely
HapLogic: A Predictive Human Leukocyte Antigen–Matching Algorithm to Enhance Rapid Identification of the Optimal Unrelated Hematopoietic Stem Cell Sources.
Likelihood of finding unrelated donor or cord blood
Likelihood of finding unrelated donor or cord blood
Presentation transcript:

Advances in HLA Matching for Unrelated Donor Transplantation Dennis L. Confer, M.D. Chief Medical Officer National Marrow Donor Program Minneapolis, Minnesota

About These Slides Our thanks to the presenters who gave permission to include their original data Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent These slides may not be published or posted online without permission from Clinical Care Options Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

4 Van Rood JJ, et al. Reprinted by permission from Macmillan Publishers Ltd.

5 Reprinted by permission from Macmillan Publishers Ltd. Van Rood JJ, et al, Nature 1958;181:

6 Milestones in Allogeneic Transplantation First allogeneic transplant – 6 related bone marrow donors 1968 – First single donor related transplants III AIAIIA BIBIIB Mom Dad

7 Likelihood of a Sibling Match Match likelihood1 – no match “n” siblings1 – (0.75) n 1 sibling1 – (0.75) 1 = siblings1 – (0.75) 2 = siblings1 – (0.75) 4 = siblings1 – (0.75) 7 = siblings1 – (0.75) 1.3 = 0.30

8 More Milestones 1973 – First unrelated donor transplants 1974 – Anthony Nolan Registry started 1986 – NMDP started in St. Paul, Minn.

9 NMDP’s Early History Dr. Bob Graves and daughter, Laura 1984 – National Organ Transplant Act 1985 – NIH Technical Assessment Panel $1.2 million Congressional Appropriation Founders – Bob Graves, Jeff McCullough, John Hansen, Herb Perkins Vice-chair -Adm. E.R. “Bud” Zumwalt, Jr.

10 National Marrow Donor Program Adult Donors & Cord Blood Units – Nov, 2008 Adult Donors 7,357,370 CBUs 91,758

11 NMDP Transplants Facilitated by Fiscal Year 1987–2008 Cord blood Peripheral blood stem cells Bone marrow

12 NMDP Transplant Recipients by Diagnosis – Selected Malignancies

13 NMDP Recipients >55 Years of Age

14 Worldwide Transplants Facilitated with Unrelated Donors by Calendar Year 1997–2007 Recipients Bone marrow Peripheral blood stem cells Cord blood (approximate)

17 National Marrow Donor Program Adult Donors & Cord Blood Units – Nov, 2008 Adult Donors 7,357,370 CBUs 91,758

18 HLA Typing by Serology Known antigens A = ~25 B = ~55 DR = ~20 Total = ~100 Known problems –Sera from donors –Many donors Caucasians –Requires live lymphocytes –Most typing for A, B only –High rate of incorrect assignments in 1990’s (>20%)

19 HLA Typing Methods Serology Identifies HLA molecules on the cell surface using antigen specific anti-sera DNA Identifies HLA molecules by defining the DNA code in the cell nucleus Antigen Protein DNA

20 HLA Nomenclature Serology A2 ….. A2 DNA A*0201 A*0202 A*0203 A*0204 A*0205 ….. A*0273 Serology DNA

21 Human MHC Region HLA-A HLA-C & B DRB1 DQA1 & B1 Chromosome 6 Regions HLA class II region loci HLA class III region loci HLA class I region loci Class IIClass IIIClass I Centromere Telomere p q 6p21.31 PSMBB9 (LMP2)TAPBPDPB2DPB1DPA1DOADMADMBTAP1TAP2PSMBB8 (LMP1)DOBDQB1DQA1DRB1DRB2DRB3DRA LTA TNF-  LTBHSPA1BHSPA1AHSPA1LC2BFC4AC4BP450, C21B MICBMICAHLA-BHLA-CHLA-EHLA-AHLA-GHLA-FHFE

22 HLA Class I and II Groove-Domain Cytoplasmic TM Class I Class II Exon 4 Exon 3 Exon Exon 3 Exon 2 Class IClass II Peptide-binding groove 11 22 33 2m2m 11 22 11 22

23 Resolution of DNA Typing Low Resolution Similar to serology e.g., A*02XX IntermediateGroups of alleles e.g., A*0201/02/04 = A*02MS High ResolutionNearly allele-level Allele levelAllele level

24 Transition to DNA-based Typing DRB1 typing –1992 –A, B typed donors A, B typing –1997 demonstration projects A, B & DR at recruitment –2000 Current File

25 DNA Issues: Explosion of Alleles Known Alleles November 2008 A = 697 B =1010 C =382 DRB1 =603

26 DNA Issues: Managing a Mixed Registry B*1501,*4001 B*15AD B62,60 B38,60 B*1502,*4001 Patient B15,40 B8,56 B*15AD,40AB >7 million in NMDP Registry

27 DNA Issues: Data Compression B*1801, B*5101 B*1807, B*5107 B*1811, B*5112 B*1801/07/11, B*5101/07/12 or B*18DFT, B*51AEH or B*18XX, B*51XX Laboratory Report 1 GAGGAGGTTAAGTTTGAG 2 GAGCTGCTTAAGTCTGAG 3 GAGCAGGTTAAACATGAG 4 GAGTACTCTACGGGTGAG 5 GAAGCAGGATAAGTTTGA 6 CAGCAGGATAAGTATGAG 7 TGGCAGCTTAAGTTTGAA 8 GTACTCTACGTCTGAGTG 9 TGGCAGGGTAAGTATAAG Etc. Laboratory Data Laboratory Interpretation

28 DNA Issues: Data Compression B*1801, B*5101 B*1807, B*5107 B*1811, B*5112 B*1801/07/11, B*5101/07/12 or B*18DFT, B*51AEH or B*18XX, B*51XX Laboratory Report 1 GAGGAGGTTAAGTTTGAG 2 GAGCTGCTTAAGTCTGAG 3 GAGCAGGTTAAACATGAG 4 GAGTACTCTACGGGTGAG 5 GAAGCAGGATAAGTTTGA 6 CAGCAGGATAAGTATGAG 7 TGGCAGCTTAAGTTTGAA 8 GTACTCTACGTCTGAGTG 9 TGGCAGGGTAAGTATAAG Etc. Laboratory Data B*1801, B*5101B*1811, B*5101 B*1801, B*5107B*1811, B*5107 B*1801, B*5112B*1811, B*5112 B*1807, B*5101 B*1807, B*5107 B*1807, B*5112 Laboratory Interpretation User’s Interpretation

29 Searching in a Mixed Registry Old Search Algorithm –Convert all typing to “Serology” –Match on serology –Examine DNA-typed donors for more New Search Algorithm – HapLogic sm –Convert serology to “DNA” –Convert low resolution DNA to high resolution

30 Understanding Haplotypes ABDRDQ C An individual’s HLA phenotype is determined by the HLA genes on the chromosome #6 inherited from each parent The phenotype is dictated by two haplotypes Haplotype from Mom Haplotype from Dad

This is the demo footer 31 Patient: A*0222 B*1504 DRB1*0901 A*2402 B*3501DRB1*1402 Sibling 1: A*02XXB*35XXDRB1*07XX A*68XX B*44XX DRB1*14XX Sibling 2: A*24XXB*15XXDRB1*07XX A*29XX B*44XX DRB1*09XX

32 HLA B-HLA C B*0801 is found with Cw*0701 about 95% of the time HLA DRB1-HLA-DQB1 DRB1*0101 is found with DQB1*0501 about 97% of the time Linkage disequilibrium

33 Strategy for Haplotype Generation Calculate high-resolution allele frequencies by race Build up estimations of extended high-resolution haplotypes Run successive 2-3 locus estimations of tightly-linked loci using modified EM (Expectation Maximization) algorithm [B-C] [DRB3/DRB4/DRB5-DRB1] [DQA1-DQB1] Consider the resulting haplotypes as a “locus” and run estimations for the loosely-linked loci A - [B-C] B - [DRB3/DRB4/DRB5-DRB1] A - [B-C] - [DRB3/DRB4/DRB5-DRB1/DQA1-DQB1]

34 bioinformatics.nmdp.org

35 Top 100 Caucasian A,B,C & DRB1 High-Resolution Haplotypes Frequency Haplotype Rank

36 Searching Patients — Haplotype Frequencies Haplotype 2 Frequency Haplotype 1 Frequency

1. Calculation for each individual locus at A, B, DRB1, DQB1 and C

2. Calculation for the overall (composite) likelihood of a 6/6, 5/6, or 4/6 allele level match across all loci - Pr(6), Pr(5)

41 DNA Issues: Data Compression B*1801, B*5101 B*1807, B*5107 B*1811, B*5112 B*1801/07/11, B*5101/07/12 or B*18DFT, B*51AEH or B*18XX, B*51XX Laboratory Report 1 GAGGAGGTTAAGTTTGAG 2 GAGCTGCTTAAGTCTGAG 3 GAGCAGGTTAAACATGAG 4 GAGTACTCTACGGGTGAG 5 GAAGCAGGATAAGTTTGA 6 CAGCAGGATAAGTATGAG 7 TGGCAGCTTAAGTTTGAA 8 GTACTCTACGTCTGAGTG 9 TGGCAGGGTAAGTATAAG Etc. Laboratory Data B*1801, B*5101B*1811, B*5101 B*1801, B*5107B*1811, B*5107 B*1801, B*5112B*1811, B*5112 B*1807, B*5101 B*1807, B*5107 B*1807, B*5112 Laboratory Interpretation User’s Interpretation

42 Primary data HLA Typing Lab NMDP Primary data HLA typing information

43 Primary data A listing of sequences that are present or absent in a donor/cord HLA typing

44 Symbol shows that primary data exists and the donor: +may be an allele match (A+, P+) ―will not be an allele match (M-, L-) #excludes at least one allele of the patient’s pair (P#) Primary data indicators

45 Primary data available No primary data available Primary data indicators Still has a low probability to match the patient at the B locus!

46 P# always describes a pair of alleles Patient’s allele pair is not present in the donor’s HLA typing P#P# = A/L, L/A or L/L The primary data does not provide enough information to tell where the allele mismatch will be located What is that P# all about? Primary data indicators

47 +–#+–# Primary data indicators

48 SUMMARY HLA has come a long way in 50 years HCT has come a long way in 22 years Advanced bioinformatics techniques are needed to: –Address the ever-changing field of HLA –Keep HLA data current and usable –Simplify and speed the process of adult donor and cord blood unit identification

49 Acknowledgments NMDP Staff Martin Maiers Neil Smeby Michelle Setterholm Histocompatibility Advisory Group Leaders and Scientists Bob Hartzman Bob Baitty Carolyn Hurley Jennifer Ng Bill Klitz Craig Kollman

Go Online for More Information on Allogeneic Transplantation! Virtual Presentations on advances in HLA matching, related vs unrelated donor transplants, and donor choice considerations for unrelated donor transplantation. Visit the NMDP site at marrow.org/md or by clicking the logo for more information on this important resource clinicaloptions.com/oncology